Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.

Journal:

The American journal of the medical sciences

Issue Date:

2018

Abstract(summary):

Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier. Copyright =C2=A9 2017 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.